SPECT/CT Device for Theranostic Imaging Debuts at EANM Meeting

News
Article

Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).

Offering enhanced sensitivity and spatial resolution capability approaching that of positron emission tomography (PET), the AnyScan Trio SPECT/CT TheraMax system was introduced at the European Association of Nuclear Medicine (EANM) annual conference in Hamburg, Germany.

Designed with an emphasis on targeted radionuclide therapy applications, the AnyScan Trio SPECT/CT TheraMax platform includes detectors and collimators that enable the use of alpha- and beta-emitting radiopharmaceuticals as well as high-energy gamma photons such as lutetium-177 (177Lu) and actinium-225 (225Ac), according to Mediso, the manufacturer of the AnyScan Trio SPECT/CT TheraMax device.

SPECT/CT Device for Theranostic Imaging Debuts at EANM Meeting

Recently installed at the University Hospital Regensburg in Regensburg, Germany, the AnyScan Trio SPECT/CT TheraMax system was designed with an emphasis on targeted radionuclide therapy applications, according to Mediso, the manufacturer of the system. (Photo courtesy of Mediso.)

The company noted that other features and capabilities of the system include:

• surface detectors up to five times larger than those utilized in 12-detector cadmium zinc telluride (CZT) platforms;

• PET-like image quality with bolstered spatial resolution facilitated by the platform’s high-density sensor arrangement;

• whole-body SPECT/CT scans with up to 300 percent higher sensitivity in comparison to conventional dual-detector devices; and

• integrated computed tomography (CT) options for low-dose, ultra-low dose and “zero-dose” protocols with artificial intelligence (AI)-enabled SyCT (Synthetic CT).

"With the development of the new TheraMAX, we extended the imaging capabilities of nuclear medicine departments by improving the diagnostic confidence of SPECT/CT examinations close to PET/CT," said Istvan Bagaméry, the managing director of Mediso. "The TheraMAX transforms the clinical routine also with ultra-fast quantitative total-body scans."

Recent Videos
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
Related Content
© 2025 MJH Life Sciences

All rights reserved.